DIGIT AL HEALTH
targeted treatments for patients with diseases such as cancer, obesity, and cardiovascular disease. Today, major technological advances are helping
to accelerate the time it takes to read, analyse, and understand genes, allowing us to discover new personalised medicines and therapies even faster. Combined with an exponential decline in sequencing costs, more clinically relevant sequencing timescales and large-scale public and pharmaceutical investment, genomics is dramatically altering the future of medicine.
Transforming healthcare The United Kingdom’s leadership in genomics is recognised globally, from the completion of the 100,000 Genome Project to COVID-19 surveillance through virus sequencing. A combination of the NHS, a strong science base, a thriving life sciences industry, private and public funding, genomics research capabilities and national institutions has allowed the UK to harness the potential of genomics to transform healthcare. The Genome UK Strategy sets out an ambition
for the UK to be the world’s most advanced genomic healthcare ecosystem. This presents opportunities to accelerate research, develop innovations in new technologies and data science, and to apply genomics in the clinical setting to diagnose disease at an earlier stage and also predict and prevent diseases before they might appear. And at the cutting-edge of Genomic healthcare, informatics tools and precision medicine evidenced
26 UKHEALTHCARE P A VILION. COM
by the Genomic surveillance of the SARS-CoV-2 virus, by world leading Wellcome Sanger Institute. The UK has achieved growth as a rate not
previously possible, led by government, supported by start-ups and scaling companies; active investors; world-leading academics; a strong skills base; unique data resources; leading research institutes; and the NHS, all joined together by their mission to improve patients’ lives. From preventing disease through early diagnosis to offering hope to patients with rare diseases, genomics is now the foundation underpinning modern medicine. The UK genomics ecosystem builds on our
long legacy in genomic research, and is in a unique position to leverage these capabilities going forwards, with strategic national public and private investments. From UK Biobank and Genomics England
through to the NHS Genomics Medicine Service, this is an exciting time for UK health innovation. The UK is fast delivering the potential of genomics technologies and we are looking to partner globally.
Madhukar Bose Deputy Head of Healthcare: Digital Health, The Department for International Trade
DUSSELDORF 2022
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
